These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 27321544)

  • 41. Correct use of proton pump inhibitors for gastro-oesophageal reflux disease.
    Hatlebakk JG; Emken BE; Glazkov V; Hoff DA; Hausken T
    Tidsskr Nor Laegeforen; 2013 Jan; 133(1):43-6. PubMed ID: 23306993
    [No Abstract]   [Full Text] [Related]  

  • 42. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis.
    Filion KB; Chateau D; Targownik LE; Gershon A; Durand M; Tamim H; Teare GF; Ravani P; Ernst P; Dormuth CR;
    Gut; 2014 Apr; 63(4):552-8. PubMed ID: 23856153
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Marked increase in proton pump inhibitors use in Australia.
    Hollingworth S; Duncan EL; Martin JH
    Pharmacoepidemiol Drug Saf; 2010 Oct; 19(10):1019-24. PubMed ID: 20623646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety.
    Savarino V; Di Mario F; Scarpignato C
    Pharmacol Res; 2009 Mar; 59(3):135-53. PubMed ID: 18977444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gastroesophageal reflux disease (GERD): is there more to the story?
    Vesper BJ; Altman KW; Elseth KM; Haines GK; Pavlova SI; Tao L; Tarjan G; Radosevich JA
    ChemMedChem; 2008 Apr; 3(4):552-9. PubMed ID: 18076011
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proton Pump Inhibitors: What the Internist Needs to Know.
    Spechler SJ
    Med Clin North Am; 2019 Jan; 103(1):1-14. PubMed ID: 30466666
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists.
    Houben E; Johansson S; Nagy P; Penning-van Beest FJA; Kuipers EJ; Herings RMC
    Curr Med Res Opin; 2018 Apr; 34(4):577-583. PubMed ID: 29149805
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gastroesophageal reflux disease.
    Armstrong D
    Curr Opin Pharmacol; 2005 Dec; 5(6):589-95. PubMed ID: 16214410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Proton pump inhibitors: placing putative adverse effects in proper perspective.
    Schubert ML
    Curr Opin Gastroenterol; 2019 Nov; 35(6):509-516. PubMed ID: 31433315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Histamine receptor antagonists, proton pump inhibitors and their combination in the treatment of gastro-oesophageal reflux disease.
    Katz PO; Tutuian R
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):371-84. PubMed ID: 11403533
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy.
    Nelson SP; Kothari S; Wu EQ; Beaulieu N; McHale JM; Dabbous OH
    J Med Econ; 2009; 12(4):348-55. PubMed ID: 19827992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evolving drugs in gastroesophageal reflux disease: pharmacologic treatment beyond proton pump inhibitors.
    Johnson DA; Levy BH
    Expert Opin Pharmacother; 2010 Jun; 11(9):1541-8. PubMed ID: 20450445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease.
    Kahrilas PJ; Howden CW; Hughes N
    Am J Gastroenterol; 2011 Aug; 106(8):1419-25; quiz 1426. PubMed ID: 21537361
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medical treatment of gastro-oesophageal reflux disease.
    De Giorgi F; Savarese MF; Atteo E; Leone CA; Cuomo R
    Acta Otorhinolaryngol Ital; 2006 Oct; 26(5):276-80. PubMed ID: 17345932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease.
    Tjon JA; Pe M; Soscia J; Mahant S
    Pharmacotherapy; 2013 Sep; 33(9):956-71. PubMed ID: 23712734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists.
    Barkun AN; Adam V; Martel M; Bardou M
    Value Health; 2013; 16(1):14-22. PubMed ID: 23337211
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy.
    Rackoff A; Agrawal A; Hila A; Mainie I; Tutuian R; Castell DO
    Dis Esophagus; 2005; 18(6):370-3. PubMed ID: 16336606
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk?
    Heidelbaugh JJ; Metz DC; Yang YX
    Int J Clin Pract; 2012 Jun; 66(6):582-91. PubMed ID: 22607510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Proton pump inhibitor H2 receptor antagonist].
    Shiotani A; Kamada T; Kusunoki H; Manabe N; Haruma K
    Nihon Rinsho; 2011 Jun; 69(6):1032-8. PubMed ID: 21688623
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proton pump inhibitor failure--what are the therapeutic options?
    Fass R
    Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S33-8. PubMed ID: 19262545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.